Total pharma industry deals for Q1 2019 worth $143.29bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 40.6% over the previous quarter and a rise of 139.3% when compared with the last four-quarter average of $59.88bn.
In terms of number of deals, the sector saw a drop of 5.9% over the last four-quarter average with 384 deals against the average of 408 deals.
In value terms, North America led the activity with deals worth $133.38bn.
Pharma industry deals in Q1 2019: Top deals
The top five pharma deals accounted for 87.4% of the overall value during Q1 2019.
The combined value of the top five pharma deals stood at $125.17bn, against the overall value of $143.29bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q1 2019 was Bristol-Myers Squibb‘s $89.54bn acquisition of Celgene.
In second place was the $21.4bn asset transaction with General Electric by Danaher and in third place was Eli Lilly’s $8bn acquisition of Loxo Oncology.
The $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and Grifols‘ stake acquisition of Shanghai RAAS Blood Products for $1.93bn held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.